EPO联合同步放化疗治疗局部晚期非小细胞肺癌的疗效观察

Observation on efficacy of EPO combined with concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer

目的观察促红细胞生成素(EPO)联合同步放化疗治疗局部晚期非小细胞肺癌(LANSCLC)患者的临床疗效。方法采用前瞻性研究,纳入2018年1月至2020年1月收治的局部晚期非小细胞肺癌患者89例作为研究对象。根据治疗方式的不同分为研究组(n=46)与对照组(n=43),对照组仅行同步放化疗,研究组采用EPO联合同步放化疗。比较两组患者治疗后Hb的变化、疗效、生存情况及不良反应情况。结果治疗后4周两组患者的Hb比较,差异有统计学意义(P<0.001)。研究组的客观缓解率(ORR)为84.78%,明显高于对照组的62.79%(P<0.05);研究组无进展生存期(PFS)优于对照组(P<0.05);两组患者总生存率及不良反应发生情况比较,差异无统计学意义(P>0.05)。结论EPO联合同步放化疗治疗局部晚期非小细胞肺癌患者,能够保持患者的Hb水平,提高近期疗效,延长生存时间,且不良反应少,安全可靠,值得临床推广应用。

Objective To observe the clinical efficacy of erythropoietin(EPO)combined with concurrent chemoradiotherapy in patients with locally advanced non-small-cell lung cancer(LANSCLC).Methods A prospective study was conducted in 89 patients with LANSCLC admitted to hospital from January 2018 to January 2020.According to different treatment methods,the patients were divided into study group(n=46)and control group(n=43).The control group only received concurrent chemoradiotherapy,and the study group received EPO combined with concurrent chemoradiotherapy.And then,the Hb changes,efficacy,survival and adverse reactions of the two groups were compared after treatment.Results 4 weeks after treatment,the difference of Hb between the two groups was statistically significant(P<0.001).The objective response rate(ORR)of the study group was 84.78%,which was significantly higher than that of the control group(62.79%)(P<0.05).The progression-free survival(PFS)of the study group was better than that of the control group(P<0.05);There was no statistically significant difference in the overall survival rate and adverse reactions between the two groups(P>0.05).Conclusion EPO combined with concurrent chemoradiotherapy for patients with locally advanced non-small-cell lung cancer can maintain patients'Hb levels,improve short-term curative effects,prolong survival time with fewer adverse reactions,which is safe and reliable,and thus is worthy of clinical application.